eGenesis was founded in 2015 by CRISPR and genomics pioneers, Drs. Luhan Yang and George Church.
Recognizing the fundamental limitations of allotransplantation, eGenesis’ mission is to save and enhance the lives of patients by delivering an alternative source of safe and effective human-compatible organs, tissues and cells.
Using world-class genome engineering expertise, eGenesis has developed a multiplexed gene editing platform with the unique capability to address the historic challenges of xenotransplantation – the process of transplanting organs, tissues or cells between members of different species.
eGenesis has the potential to make a significant impact on the millions of patients globally in need of life-saving organs as well as those suffering from end-stage organ disease.